Talking Techniques

Share

Microbiome profiling techniques: from immunology to agriculture

Season 3, Ep. 13

In this episode of the Talking Techniques podcast, we explore microbiomes and the techniques used to profile them. Get an overview of the different techniques’ working principles, their pros and cons and the different applications that they are best suited to.


Providing an expert insight into this field is Annabelle Damerum, Microbiome R&D Scientist at Zymo Research. Annabelle reveals some key tips best practice when profiling the microbiome and details the importance of an emerging aspect of the field: the vaginal microbiome.


Contents:
  • Into: 00:00-01:50
  • Why it is important to profile microbiomes. 01:50-04:15
  • Key applications of microbiome profiling: 04:15-06:10
  • Techniques used to profile the microbiome and their working principles: 06:10-09:20
  • Targeted sequencing: 06:10-08:00
  • Shotgun metagenomics: 08:00-09:00
  • Metatranscriptomics: 09:00-9:15
  • The strengths and limitations of these techniques: 09:12-             
  • Targeted sequencing: 09:20-10.15
  • Shotgun metagenomics: 10:15-11:25
  • Metatranscriptomics: 11:25-11:50
  • Matching techniques with applications: 11:50-13:30
  • Tips for best practice for using these techniques: 13:30-16:25
  • What is one thing you would ask for to improve the ability of microbiome profiling techniques: 16:55-18:10
  • Investigating the vaginal microbiome: 18:10-20:55
  • Conclusions and closing: 20:55-22:10

 

More Episodes

8/26/2022

3D cell cultures: the latest developments, applications and regulations in the field

Season 3, Ep. 11
In this episode, supported by BrandTech, returning guest Rob Vries, CEO of HUB organoids (Utrecht, The Netherlands), fills us in on the advancement of 3D cell cultures and organoids over the last 2 years, starting off by documenting how the pandemic impacted their development and uptake.We also discuss how the recent FDA Modernization Act, removing the requirement for drug candidates to be tested on animals, has impacted the drive for improved models, the key techniques available to analyze them and what still needs to change for 3D cell cultures to fully replace animal models in the lab.Listen today to find out which resources can help you begin to work with 3D cell cultures, their most exciting recent applications and how issues of reproducibility are currently being addressed in the field.Contents:Intro: 00:00-00:50How COVID-19 impacted the uptake and development of 3D cell cultures: 00:50-02:05Key developments in 3D cell culture technology in the last 2 years: 02:05-03:00Intestinal organoids and the investigation of irritable bowel syndrome: 03:00-5:50Evaluating assembloids: 05:50-08:35Complexity vs clinical relevance: 08:35-10:45The impact of 3D cell cultures in precision medicine in cancer: 10:45-12:40The impact of the FDA’s Modernization Act on 3D cell culture uptake: 12:40-14:45What needs to improve in organoid technologies to fully replace animal models? 14:45-16:10Changing inbuilt reliance on animal models: 16:10-18:30Key techniques to analyze organoids: 18:30-19:50Developments in imaging technology that have improved the analysis of organoids: 19:50-21:15Current challenges in 3D cell culture implementation and reproducibility: 21:15-24:15Improving access to 3D cell cultures: 24:15-25:55Resources to help people implement organoids into their work: 25:55-27:15Searching for the holy grail in 3D cell cultures: 27:15-28:00
8/3/2022

rAAVs, host-cell contamination and ddPCR

Season 3, Ep. 10
In this episode of Talking Techniques, supported by Bio-Rad, we discuss a key component of many gene therapies: recombinant adeno-associated viruses (rAAVs) and their production. These viruses act as efficient, accurate delivery vesicles for the gene therapy’s plasmid.Speaking to Associate Director of Biopharma Product Marketing at Bio-Rad Laboratories, Mark White, we take a look at the different expression systems used for their production and compare their advantages, before looking at some of the challenges involved in the production rAAVs, such as host-cell contamination.Discover the tools that can help minimize host-cell contamination and differentiate between nuclease resistant and nuclease reactive contaminant DNA and find out about some of the most exciting developments in rAAV technologies. Contents:The role of rAAVs in gene therapies: 00:40-02:15The production of rAAVs and gene therapies: 02:15-03:30Why are HEK cells so popular for cell therapy production? 03:30-05:45HEK vs SF9 Insect cell expression systems: 05:45-06:45Challenges in cell therapy expression systems: 06:45-08:05Host DNA contamination: 08:05-10:30The risks of host DNA contamination: 10:30-12:45Key techniques to minimize host DNA contamination: 12:45-14:40The advantages of ddPCR in gene therapy production: 14:40-17:50Distinguishing between nuclease resistant and nuclease reactive host cell DNA: 17:50-19:10The most exciting developments in rAAV technology: 19:10-20:20What is one thing you would ask for to improve rAAV and gene therapy development 20:20-26:38
7/28/2022

HPV, epigenetics and cancer: sequencing for new insights and to correct healthcare inequality

Season 3, Ep. 9
In many regions of the world, HPV and its association with cervical cancer is a well-known but rarely considered issue, after the rollout of the HPV vaccine in the late 2000s. However, while this rollout significantly impacted cervical cancer rates where it was implemented, it was not universal and in many areas of the world HPV-induced cervical cancer remains a critical issue.Cervical cancer is the leading cause of death for people with a cervix living in poverty in low-resource regions and on the continent of Africa, it is estimated that in 2020 as many people with a cervix died of cervical cancer as COVID-19.In this episode of Talking techniques, supported by Oxford Nanopore, Senior Investigator Michael Dean and Post-baccalaureate Fellow Nicole Rossi, from the NIH’s National Cancer Institute (MD, USA), discuss their research into the relationship between HPV and cervical cancer. Expounding on the points mentioned above, they reveal the tremendous insights into cancer and immunology still to be gained, document the key tools used in their studies and explain how their work can be translated into more effective immunotherapies and treatments for cervical cancer.ContentsIntroduction: 00:00-01:40How big an issue does HPV present to the world? 01:40-03:30HPV’s association with cancer: 03:30-05:15Why does HPV target DNA repair mechanisms? 05:15-06:00Key goals of research into HPV: 06:00-07:15Challenges of HPV research: 07:15- 08:20Solutions available to deal with these challenges: 08:20-09:30The most exciting discoveries in HPV using long-read sequencing: 09:30-11:00HPV16- the most oncogenic variant: 11:00-11:40Translating research into clinical results for HPV: 11:40-12:45How effective is the current HPV vaccine? 12:45-13:30What would you ask for to improve research into HPV and cancer? 13:30-14:30How big an issue is vaccine rejection? 14:30-15:40Final thoughts: 15:40-17:00